Biotech Values

[mcbio]

These guys are very late on P13K.

Yes, definitely late on PI3K. But, they are the only company I know of with a dual PI3K/MNK inhibitor. So, at least they are differentiated in some angle. Time will tell if that means anything or not, of course.

Looks like a potential case of Supergen II, take the good (royalties) and toss it at middling r&d.

I think the PSMA ADC is interesting and I don't think of that as middling. As PGNX noted, the antigen is potentially applicable beyond prostate cancer as well. Sounds like they are in discussion with potential partners on the drug. We'll see if those discussions bear fruit down the road. I imagine it will depend on the final Phase 1 results and if the drug truly has activity, as PGNX seems to be hinting at.

I still think Relistor is the real big key for PGNX in the near-term though.